These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26024723)

  • 1. Acceptance Probability (P a) Analysis for Process Validation Lifecycle Stages.
    Alsmeyer D; Pazhayattil A; Chen S; Munaretto F; Hye M; Sanghvi P
    AAPS PharmSciTech; 2016 Apr; 17(2):516-22. PubMed ID: 26024723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage 2 Process Performance Qualification (PPQ): a Scientific Approach to Determine the Number of PPQ Batches.
    Pazhayattil A; Alsmeyer D; Chen S; Hye M; Ingram M; Sanghvi P
    AAPS PharmSciTech; 2016 Aug; 17(4):829-33. PubMed ID: 26349690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A.
    Howard-Sparks M; Gawlikowski A;
    PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the probability of passing the USP dissolution test.
    Wang H
    J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment Methodology for Process Validation Lifecycle Stage 3A.
    Sayeed-Desta N; Pazhayattil AB; Collins J; Chen S; Ingram M; Spes J
    AAPS PharmSciTech; 2017 Jul; 18(5):1881-1886. PubMed ID: 27714700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical properties of the USP dissolution test with pooled samples.
    Saccone CD; Meneces NS; Tessore J
    PDA J Pharm Sci Technol; 2005; 59(5):310-9. PubMed ID: 16316066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical method transfer: new descriptive approach for acceptance criteria definition.
    de Fontenay G
    J Pharm Biomed Anal; 2008 Jan; 46(1):104-12. PubMed ID: 17961955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PAT-based qualification of pharmaceutical excipients produced by batch or continuous processing.
    Hertrampf A; Müller H; Menezes JC; Herdling T
    J Pharm Biomed Anal; 2015 Oct; 114():208-15. PubMed ID: 26072012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptance criteria for method equivalency assessments.
    Chatfield MJ; Borman PJ
    Anal Chem; 2009 Dec; 81(24):9841-8. PubMed ID: 19925004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Content uniformity acceptance limit for a validation batch--suppositories, transdermal systems, and inhalations.
    Senderak ET
    Drug Dev Ind Pharm; 2009 Jun; 35(6):735-7. PubMed ID: 19514989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of analytical methods involved in dissolution assays: acceptance limits and decision methodologies.
    Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P
    Anal Chim Acta; 2012 Nov; 751():44-51. PubMed ID: 23084050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space.
    Eon-duval A; Valax P; Solacroup T; Broly H; Gleixner R; Strat CL; Sutter J
    J Pharm Sci; 2012 Oct; 101(10):3604-18. PubMed ID: 22821774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study: application of statistical process control tool for determining process capability and sigma level.
    Chopra V; Bairagi M; Trivedi P; Nagar M
    PDA J Pharm Sci Technol; 2012; 66(2):98-115. PubMed ID: 22492596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.